Reportlinker Adds Physician Office Laboratory (POL) Testing Markets Worldwide: Status Quo and Future Trends

NEW YORK, Nov. 3, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Physician Office Laboratory (POL) Testing Markets Worldwide: Status Quo and Future Trends

http://www.reportlinker.com/p049677/Physician-Office-Laboratory-POL-Testing-Markets-Worldwide-Status-Quo-and-Future-Trends.html

This report is the second edition of the report "Physician Office Testing, Worldwide: Status Quo and Future Trends" that was first published in 2007. The report concentrates on how the market for POL testing has evolved from 2007 to 2010.

The report takes a bold look into the technologies and trends in physician office testing and laboratories (POLs) with a special focus on the economics of test use in on-site patient care. The report is conservative in its predictions and offers a calculated look into the future, based on events taking place in the present.

The term physician office lab (POL) is as wide and diverse as one can imagine. It encompasses physician practices as small as 2 to 5 doctors that perform a few rapid tests to large practices of some 200 physicians that operate labs similar to small hospital laboratories. The definition used here is therefore broad and refers to the market for tests which are:

Performed in a physician office setting, At the time of a consultation between a physician or other healthcare professional (nurse practitioner, pharmacist, provides a result to be used during the medical visit and, is used for screening, diagnosis or monitoring purposes.

Growth in physician office testing is fueled by trends in preventative medicine and proactive approaches in treating the increasing number of diagnosed diabetics; by the globalization of infectious diseases and the associated public health issues; and by the need to monitor the explosion of people with cardiovascular disease and other chronic conditions.

The report offers a quantitative assessment of specific markets, worldwide, in U.S. dollars for 2009 to 2014. This data is provided in order to set the status quo of tests and technologies. However the report concentrates on how these will impact the economics of healthcare over the near term and longer when possible.

This exhaustive report provides:

• Discussions of the Regulatory Environment for POLs in various countries and regions.
• The Top POL-conducted Tests and average reimbursement level.
• POL Test Revenues by Type of Test, 2009-2014, for more than 35 test segments.
• POL Test Revenues by Region (Europe, Asia, US) , 2009 to 2014.
• Breakout of the Number of POLS in the US by type (CLIA-waived, non-waived)
• Complete discussions of the POL environments in top geographic markets.
• Profiles of the POL Offerings of over 75 suppliers.
• Market Analyses for Key POL Testing Areas.

including:

• Chemistry panels
• Coag PT
• Lipids
• Hemato - CBC
• Glucose
• HbA1c
• Rapid Flu
• Anemia ferritin, iron
• Preg/LH
• Urinalysis
• PSA
• TSH
• FOB
• Cardiac Markers
• Hepatitis
• HIV
• Histology
• Microbiology culture
• Atrep A
• Autoimmune
• Sed rate
• H. pylori
• Cancer Markers
• CRP
• Hgb
• Respiratory Viruses
• STDs
• Allergy
• DAU
• Infectious diseases
• Microalbumin
• TDM
• Other

The world market for the POL sector of point-of-care diagnostics is provided in U.S. dollars for the years 2009 - 2014. No adjustments have been made to the market data for the effects of currency exchange fluctuations or inflation. This may seem problematic, given the drastic devaluation of the U.S. dollar versus the Japanese Yen, euro and Swiss Franc. Kalorama has decided to use a constant exchange rate because it is a more accurate reflection of actual revenue growth in dollars rather than growth due to exchange rate fluctuations.

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Size and Growth of the Market

Market Trends

CHAPTER TWO: INTRODUCTION

Background

POL definition

The pros and cons of POL testing

Point of View

CHAPTER THREE: MARKET AND TECHNOLOGICAL DYNAMICS IN POL TESTING

Background

The Emergence of Non-invasive Technologies

Saliva

Breath

Optical Techniques

Miniaturization and Microfluidics Support POC

CLIA Waived Test Menu Expansion Drives U.S. POLs

Connectivity Imperative for POC devices

CHAPTER FOUR: THE ECONOMICS OF POL TESTING

Background

Reimbursement Challenges and Developments

POLs and Clinical Outcomes Management

POL Management Considerations

The Regulatory Environment for POLs

CHAPTER FIVE: POL TESTING IN WORLD MARKETS

Background

Overview of the POL Market, Worldwide

Specific Country Information

The United States of America

Europe—Many Countries and Systems

Japan

China

India

Australia

CHAPTER SIX: MARKET ANALYSIS

Market Overview

The Major Players

Disease Burden and POL Testing Needs

Test Segment Market Analysis

Diabetes - Glucose

Diabetes - HbA1c

Diabetes - Microalbumin

Cardiac Markers

Lipid Panels and Miscellaneous Cardiac Markers

Cancer Markers

Clinical Chemistry

Coagulation

Hematology

Histology

Infectious Diseases

Public Health in Developing Countries

Immunoassays

Thyroid Function

Anemia

Allergy

Autoimmune

Drugs of Abuse (DAU)

Therapeutic Drug Monitoring (TDM)

Microbiology

Molecular

Women's Health / Pregnancy/Fertility

Commercial Outlook

CHAPTER SEVEN: TOP COMPANIES

Abbott Diagnostics

Alere Inc.

ARKRAY

Bayer Diabetes Care

Becton, Dickinson and Company (BD)

Beckman Coulter Inc.

bioMerieux Inc.

Bio-Rad Laboratories Inc.

Horiba Medical

Instrumentation Laboratory (IL)

Lifescan Inc.

Ortho Clinical Diagnostics (OCD)

Phadia AB

QIAGEN N.V.

Radiometer A/S

Roche Diagnostics

Siemens Healthcare Diagnostics

Sysmex Corporation

CHAPTER EIGHT: "NEW FRONTIER" COMPANIES IN THE POL MARKET

3M Medical Diagnostics

77 Elektronika Kft.

Abaxis, Inc.

A/C Diagnostics

Accumetrics

Acon Laboratories, Inc.

Acrongenomics Inc.

Akers Biosciences, Inc.

Alfa Wassermann Diagnostic Technologies, LLC

Ani Biotech Oy

Axis-Shield plc

Biomerica Inc.

BioVei Incorporated

Carolina Liquid Chemistries Corp.

Celerus Diagnostics

Cepheid

Chembio Diagnostic Systems, Inc.

Chempaq A/S

Claros Diagnostics, Inc.

CoaguSense, Inc.

diaDexus, Inc.

Diaglobal GmbH

Diazyme Laboratories

DxNA

Eiken Chemical Co., Ltd

Enigma Diagnostics Limited

Enterix Inc.

ESA Biosciences Inc.

HandyLab, Inc.

Helena Laboratories

HemoCue AB

Idaho Technology

Innovative Biosensors

International Technidyne Corp (ITC)

LifeAssays AB

LifeSign LLC

MACHEREY-NAGEL GmbH & Co.

Meridian Bioscience, Inc.

Micronics Inc.

Nanosphere, Inc.

OraSure Technologies, Inc.

Oxonica Diagnostics

Philips Handheld Immunoassays

Pocared Diagnostics Ltd

Polymedco, Inc.

Polymer Technology Systems, Inc.

QBC Diagnostics, Inc.

QuantRx Biomedical Corporation

Quidel Corporation

Quotient Diagnostics

Randox

Response Biomedical Corp.

Rheonix Inc.

Screening Devices Canada, Inc.

SQI Diagnostics Inc.

Trinity Biotech plc

TwistDx, Ltd.

Veredus Laboratories Pte

Vital Diagnostics

CHAPTER NINE: THE FUTURE OF THE POL MARKET: SWOT ANALYSIS

Strengths

Weaknesses

Opportunities

Threats

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Historic Exchange Rate Data

Table 1-2: Worldwide POL Diagnostic Reagent Sales by country, 2009-2014 ($ million)

CHAPTER THREE: MARKET AND TECHNOLOGICAL DYNAMICS IN POL TESTING

Table 3-1: Selected Innovations in non-invasive testing, 2010

Table 3-2: Selected disease markers in exhaled breath

Table 3-3: Selected biochip and biosensor innovations, 2010

Table 3-4: Traditional CLIA waived tests

Table 3-5: Selected Waived Test Categories 2010

Table 3-6: Selected Waived Instruments and Devices 2010

Table 3-7: POLs in the U.S., 2000-2010

Table 3-8: Tests performed in-office

Table 3-9: Tests sent out to a laboratory

CHAPTER FOUR: THE ECONOMICS OF POL TESTING

Table 4-1: Selected chemistry and hematology POL systems

CHAPTER FIVE: POL TESTING IN WORLD MARKETS

Table 5-1: Worldwide POL Diagnostic Reagent Sales by Country, 2009-2014 ($ million)

Table 5-2: Overview of POLs by Country

Table 5-3: Distribution of lab tests in physician offices

Table 5-4: Top 25 POL Tests, U.S., 2009

CHAPTER SIX: MARKET ANALYSIS

Table 6-1: Worldwide POL Diagnostic Reagent Sales by test segment, 2009-2014 ($ million)

Table 6-2: POC Test Revenues of Selected Companies, Global, Estimated

Table 6-3: Selected Disease Statistics, Worldwide, 2008

Table 6-4: Selected Blood Glucose Test Devices on the Market, 2010

Table 6-5: Selected HbA1c Tests and Devices, 2010

Table 6-6: Selected Microalbumin Tests, waived

Table 6-7: Selected Cardiac Market Tests and Systems

Table 6-8: Worldwide Sales, Selected Cardiac Marker IVDs, 2009

Table 6-9: Selected Rapid CRP Diagnostics

Table 6-10: Selected Lipid Panel Tests

Table 6-11: Selected Small Footprint Chemistry Systems, 2009

Table 6-12: Selected CLIA Waived PT Devices

Table 6-13: Selected Platelet Function Tests

Table 6-14: Selected Small Footprint Hematology Systems, 2010

Table 6-15: Selected POC Hemoglobin Test Systems

Table 6-16: Worldwide POL Infectious Disease Rapid Test Sales, 2009-2014 ($ million)

Table 6-17: Worldwide POL Immunoassay Test Sales, 2009-2014 ($ million)

Table 6-18: Selected Compact Immunoassay Systems, 2010

To order this report:

Diagnostics Industry: Physician Office Laboratory (POL) Testing Markets Worldwide: Status Quo and Future Trends

Diagnostics Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker